NASDAQ · Biotechnology

TSHA (TSHA) Stock

$5.86 -0.26% NASDAQ: TSHA Healthcare

Valuation

MetricValue
Price$5.86
Market Cap$1.87B
P/E Ratio-13.49
P/B Ratio8.09
P/S Ratio199.95
EPS (TTM)$-0.41
52-Week High$7.30
52-Week Low$2.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-97.28%
ROA-37.77%
ROCE-44.53%
Gross Margin88.22%
Operating Margin-17.74%
Net Margin-17.38%
Debt/Equity0.08
Current Ratio12.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$3.0M$15.0M$8.0M$10.0M
Operating Profit$-173.0M$-126.0M$-72.0M$-91.0M$-110.0M
Net Profit$-175.0M$-166.0M$-112.0M$-89.0M$-109.0M
EPS$-4.64$-3.78$-0.96$-0.36$-0.34
Op Margin—-5037.1%-468.8%-1097.5%-1130.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$214.0M$126.0M$173.0M$160.0M$343.0M
Total Liabilities$119.0M$125.0M$98.0M$89.0M$96.0M
Cash$149.0M$88.0M$144.0M$139.0M$320.0M
Borrowings$63.0M$60.0M$61.0M$63.0M$18.0M

Latest News

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In Insider Monkey · Jul 15, 2026 Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing MT Newswires · Jul 13, 2026 Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run Motley Fool · Jul 12, 2026 Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting GlobeNewswire · Jun 25, 2026 Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-117.0M$-88.0M$-73.0M$-81.0M$-93.0M
Investing Cash Flow$-43.0M$-50.0M$-15.0M$-1.0M$-1.0M
Financing Cash Flow$-1.0M$-1.0M$-1.0M$0$0
Net Cash Flow$-100.0M$-61.0M$56.0M$-5.0M$181.0M
Free Cash Flow$-139.0M$-113.0M$-80.0M$-82.0M$-94.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-10.90
FCF Yield-7.72%
Quick Ratio14.04
Interest Coverage—
Return 1Y116.73%
Return 3Y770.15%
Return 5Y-70.96%

Ownership

Insiders Held9.63%
Institutions Held86.20%
Institutions Float Held95.38%
Institutional HolderSharesReport Date
RA Capital Management, L.P.23,555,6482026-03-31
Goldman Sachs Group Inc22,369,6452026-03-31
Avoro Capital Advisors LLC21,700,0002026-03-31
Blackrock Inc.18,365,6082026-03-31
Vestal Point Capital, LP18,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
DNTH $104.09 +2.44% -17.99 $4.35B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%

About TSHA

TSHA is led by CEO Sean Nolan, employs 73 people, headquartered in US, publicly traded since 2020.

TSHA stock trades at $5.86 with a market capitalization of $1.87B. The stock is valued at a price-to-earnings (P/E) ratio of -13.49, price-to-book of 8.09, price-to-sales of 199.95. Over the past 52 weeks the stock has ranged between $2.25 and $7.30, and currently trades 19.7% below its 52-week high.

On profitability, TSHA generates a return on equity (ROE) of -97.28%, return on capital employed of -44.53%, an operating margin of -17.74%, a net profit margin of -17.38%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides